Catalyst
Slingshot members are tracking this event:
AbbVie (ABBV) Phase 2 Data Evaluating ABT-494 in Crohn's Disease Expected in H1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABBV |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 09, 2017
Occurred Source:
https://news.abbvie.com/news/press-releases/abbvie-announces-positive-phase-2-study-results-for-upadacitinib-abt-494-an-investigational-jak1-selective-inhibitor-in-crohns-disease.htm
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Abt-494, Crohn's Disease
